Evaluation of cardiovascular risk in patients with Parkinson disease under levodopa treatment

BACKGROUND: Levodopa is the indispensable choice of medial therapy in patients with Parkinson disease (PD). Since L-dopa treatment was shown to increase serum homocysteine levels, a well-known risk factor for cardiovascular disorders, the patients with PD under L-dopa treatment will be at increased...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Geriatr Cardiol
Autors principals: Günaydın, Zeki Yüksel, Özer, Fahriye Feriha, Karagöz, Ahmet, Bektaş, Osman, Karataş, Mehmet Baran, Vural, Aslı, Bayramoğlu, Adil, Çelik, Abdullah, Yaman, Mehmet
Format: Artigo
Idioma:Inglês
Publicat: Science Press 2016
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4753016/
https://ncbi.nlm.nih.gov/pubmed/26918017
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.11909/j.issn.1671-5411.2016.01.003
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars